IX001 TCR-T
/ Shanghai Bintie Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 30, 2025
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
(clinicaltrials.gov)
- P1 | N=9 | Recruiting | Sponsor: Sun Yat-sen University | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Pancreatic Cancer • Solid Tumor
March 27, 2025
A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation
(clinicaltrials.gov)
- P1 | N=9 | Not yet recruiting | Sponsor: Sun Yat-sen University
New P1 trial • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
August 16, 2024
The clinical trial application of IX001 TCR-T injection of Bintie Biotech in China has been accepted for pancreatic cancer [Google translation]
(myimm.net)
- "On July 12, the Drug Review Center of the National Medical Products Administration showed that the clinical trial application for IX001 TCR-T injection submitted by Bintie Biopharma has been accepted. IX001 TCR-T injection is a TCR-T cell therapy targeting KRAS G12V mutation and is used to treat pancreatic cancer."
Trial status • Pancreatic Cancer
July 05, 2024
IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Shanghai Pudong Hospital
Metastases • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
1 to 4
Of
4
Go to page
1